Nyxoah Secures $15 Million EIB Loan to Fuel U.S. Expansion
Event summary
- Nyxoah received $15 million from the European Investment Bank as the second tranche of its loan facility.
- The funding, combined with a June equity raise, brings total capital raised this month to $110 million.
- Proceeds will accelerate the U.S. commercial launch of the Genio system and support R&D and manufacturing scale-up.
- The non-dilutive financing strengthens Nyxoah's balance sheet without diluting existing shareholders.
The big picture
Nyxoah's $15 million EIB loan complements its recent equity raise, positioning the company to expand its Genio system in the U.S. This move aligns with broader trends in medical technology, where non-dilutive financing is increasingly used to fuel growth without diluting shareholder value. The strategic focus on OSA treatment reflects the growing recognition of sleep disorders as a critical healthcare area with significant market potential.
What we're watching
- U.S. Market Penetration
- How Nyxoah will leverage the new capital to accelerate Genio's commercial launch in the U.S. and compete with established players.
- R&D Investment
- Whether the funding will sustain Nyxoah's innovation pipeline and support the scale-up of manufacturing.
- Financial Strategy
- The pace at which Nyxoah can maintain a strong balance sheet while pursuing aggressive growth.
Related topics